Literature DB >> 24520526

Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?

Panagiotis J Vlachostergios1, Christos N Papandreou1.   

Abstract

Neuroendocrine (NE) differentiation of cancer and deregulation of the ubiquitin-proteasome system (UPS) are two processes that have been independently linked to the development of aggressive and treatment-resistant tumors. Striking data suggest a plausible interconnection between these two mechanisms, based on indirect evidence of neuropeptide-induced effects on UPS, reversed by proteasome inhibition and deubiquitinase-like properties of NE markers. Deciphering the model of their exact interactions is one of the keys to targeting the NE malignant phenotype more effectively.

Entities:  

Keywords:  Cancer; Neuroendocrine differentiation; Proteasome; Ubiquitin

Year:  2011        PMID： 24520526      PMCID： PMC3905580          DOI： 10.5493/wjem.v1.i1.7

Source DB:  PubMed          Journal:  World J Exp Med        ISSN： 2220-315X


  12 in total

Review 1.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

2.  Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.

Authors:  Dhana E Larsson; Henrik Lövborg; Linda Rickardson; Rolf Larsson; Kjell Oberg; Dan Granberg
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

3.  Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Authors:  J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

Review 4.  New medical strategies for midgut carcinoids.

Authors:  Ola Nilsson; Yvonne Arvidsson; Viktor Johanson; Eva Forssell-Aronsson; Hâkan Ahlman
Journal:  Anticancer Agents Med Chem       Date:  2010-03       Impact factor: 2.505

5.  The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.

Authors:  Dhana E Larsson; Malin Wickström; Sadia Hassan; Kjell Oberg; Dan Granberg
Journal:  Anticancer Res       Date:  2010-01       Impact factor: 2.480

6.  Up-regulation of expression of the ubiquitin carboxyl-terminal hydrolase L1 gene in human airway epithelium of cigarette smokers.

Authors:  Brendan J Carolan; Adriana Heguy; Ben-Gary Harvey; Philip L Leopold; Barbara Ferris; Ronald G Crystal
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

7.  Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.

Authors:  Lyuba Levine; Joseph A Lucci; Barbara Pazdrak; Ji-Zhong Cheng; Yan-Shi Guo; Courtney M Townsend; Mark R Hellmich
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.

Authors:  Manisha H Shah; Donn Young; Hedy L Kindler; Iain Webb; Barbara Kleiber; John Wright; Michael Grever
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

9.  MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.

Authors:  Jui-yu Chen; Mackenzie R Cook; Scott N Pinchot; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Surg Res       Date:  2010-01       Impact factor: 2.192

10.  LYRIC/AEG-1 overexpression modulates BCCIPalpha protein levels in prostate tumor cells.

Authors:  S C Ash; D Q Yang; D E Britt
Journal:  Biochem Biophys Res Commun       Date:  2008-04-25       Impact factor: 3.575
View more
  1 in total

1.  Cytokines, Proliferation Markers, Antimicrobial Factors and Neuropeptide-Containing Innervation in Human Nasal Mucosa after Rhinoseptoplasty Procedure.

Authors:  Marija Podlesnaja; Mara Pilmane; Gunta Sumeraga
Journal:  Med Sci (Basel)       Date:  2021-04-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.